Ecologic imprint and taxi costs associated with different fractionation schedules for prostate cancer radiotherapy: An exemplary calculation from Thuringia, that makes you think …

Author:

Wurschi Georg W.1,Graf Maximilian1,Weimann Steffen1,Straube Christoph2,Domschikowski Justus3,Münter Marc4,Pietschmann Klaus1

Affiliation:

1. Jena University Hospital

2. Klinikum Landshut

3. University Hospital Schleswig-Holstein

4. Klinikum Stuttgart

Abstract

Abstract Background In times of climate change, energy transition, an aging population and skyrocketing social costs, improving the sustainability and cost-effectiveness of healthcare systems has become increasingly relevant. We evaluated three internationally established fractionation schedules for prostate cancer radiation therapy (RT) with respect to their ecological and health-economic impacts.Methods We analyzed the data of 109 patients with prostate cancer, who underwent outpatient radiation therapy at Jena University Hospital in 2022. Using the distance between their homes and our facility, carbon dioxide (CO2)-emissions and taxi costs were estimated for normofractionated RT (39 fractions), moderately hypofractionated RT (20 fractions) and ultrahypofractionated RT (5 fractions).Results Travel distances of 1616 km, 848 km and 242 km were calculated with corresponding costs ranging from 638 € (ultrahypofractionated RT) to 4255 € (normofractionated RT). The travel distance, CO2-emissions and transportation costs could be reduced by up to 85% by hypofractionation.Conclusion (Ultra-)hypofractionated radiation therapy for prostate cancer has great potential to protect the environment and lower healthcare costs. From this point of view, it should be regarded as new standard of care. However, the new short-term concepts place high demands on the accuracy of dose application which causes increased (technical and personnel) effort. To facilitate general use, adequate pricing structures and reimbursement mechanisms need to be established in the German health care system, ensuring equitable access to this innovative treatment option for all eligible patients.

Publisher

Research Square Platform LLC

Reference26 articles.

1. Datenbankabfrage mit Schätzung der Inzidenz. Prävalenz und des Überlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten 10.18444/5.03.01.0005.0017.0001 (2022). Accessed 05/03/ 2024.

2. Prostatakarzinom S3-L. Langversion 6.2. AWMF Registernummer: 043/022OL. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF; 2021. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostatatkarzinom/Version_6/LL_Prostatakarzinom_Langversion_6.2.pdf.

3. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology;Schaeffer EM;J Natl Compr Canc Netw,2023

4. Fallpauschalen-Katalog gemäß § 17b Absatz 1 Satz 4 des Krankenhausfinanzierungsgesetzes. Katalog ergänzender Zusatzentgelte gemäß § 17b Absatz 1 Satz 7 des Krankenhausfinanzierungsgesetzes, Pflegeerlöskatalog gemäß § 17b Absatz 4 Satz 5 des Krankenhausfinanzierungsgesetzes. Institut für das Entgeltsystem im Krankenhaus; 2022. https://www.g-drg.de/ag-drg-system-2023/fallpauschalen-katalog/fallpauschalen-katalog-20232. Krankenhausfinanzierungsgesetz (KHG).

5. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial;Dearnaley D;Lancet Oncol,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3